Velcade’s New SubQ Formulation Means More To Takeda Than An Incremental Advance
This article was originally published in PharmAsia News
Executive Summary
Market leading multiple myeloma treatment Velcade’s newly approved subcutaneous formulation offers greatly reduced rates of peripheral neuropathy compared to the standby intravenous formula and with similar survival data, a new marketing advantage in the face of next-generation challenges.
You may also be interested in...
FDA Accepts Onyx’s Carfilzomib Application But Denies Priority Review
“Our plan is to continue our dialogue with the FDA and see if we can address their concerns and get the accelerated approval done,” Onyx R&D chief Love told analysts. The company completed its application to treat patients with refractory and relapsed multiple myeloma in September based on results of a single-arm study, a design the agency may not be inclined to accept.
Millennium Withdraws Velcade Follicular Lymphoma sNDA, Citing Business Decision
The company will continue to evaluate bortezomib in follicular lymphoma subgroups as part of its larger development program for the first-in-class proteasome inhibitor.
Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris
Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.